Table 3.
Parameters of minimal and advanced liver disease at baseline in non-alcoholic fatty liver disease/primary biliary cholangitis and non-alcoholic fatty liver disease alone patients
| NAFLD/PBC (N = 68) | NAFLD (N = 136) | P value | |||
|---|---|---|---|---|---|
| Mean ± SD | Range | Mean ± SD | Range | ||
| FIB-4 | 1.7 ± 1.1 | 0.4–6.6 | 1.9 ± 1.4 | 0.4–8.7 | 0.26 |
| FIB-4 <1.45 (minimal or no fibrosis) | 44% | 50% | 0.41 | ||
| FIB-4 >3.25 (cirrhosis) | 7.8% | 13% | 0.26 | ||
| APRI | 0.6 ± 0.5 | 0.09–3.3 | 0.6 ± 0.5 | 0.16–3.5 | 0.99 |
| APRI ≤0.45 (minimal fibrosis) | 45% | 42% | 0.65 | ||
| APRI ≥1.5 (cirrhosis) | 4.7% | 8.1% | 0.56 | ||
APRI, aspartate aminotransferase/platelet ratio index; Fib-4, fibrosis score; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cholangitis.